Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Prospective, Open-label, Single-arm, 12-weeks, Phase IV Trial to Evaluate the Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia

NCT02106182 is registered in ClinicalTrials.gov with JW Pharmaceutical as lead sponsor.

NCT NCT02106182
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02106182 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Prospective, Open-label, Single-arm, 12-weeks, Phase IV Trial to Evaluate the Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia
Lead sponsor
JW Pharmaceutical
Phase
Phase 4
Overall status
Completed
Start date
January 2, 2014
Completion date
August 1, 2016
Enrollment
135 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

benign prostatic hyperplasia, nocturia